Significant Efficacy Demonstrated with the Combination of Ulixertinib (ERK1/2 Inhibitor) and CDK4/6 Inhibitors in MAPK Altered ModelsCaroline M. Emery,Brian Corgiat,Justin Davis,David Sorrell, Mitch Johnson,Brent Kreider,Deborah KnoerzerCancer Research（2022）引用 1|浏览4AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
